MIS-C: post-infectious syndrome or persistent infection?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Evaluation of 601 children with multisystem inflammatory syndrome (Turk MISC study).European journal of pediatrics · 2023
   Observational
2. Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents-a Live Systematic Review and Meta-analysis.Current pediatrics reports · 2022
   Review
3. Multisystem inflammatory syndrome in childrenTurkish journal of medical sciences · 2021
   Review
4. SARS-CoV-2-related multisystem inflammatory syndrome in an immunocompromised child with leukemia.Pediatric blood & cancer · 2021
   Article
5. Pathogenesis and treatment of cytokine storm in COVID-19.Turkish journal of biology = Turk biyoloji dergisi · 2021
   Review

Corrections and comments

• Comment on
  Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19.2020
• Comment on
  COVID-19 and multisystem inflammatory syndrome in children and adolescents.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as